MINNEAPOLIS, Minnesota — GT Urological wants to raise $1 million to continue with research and development of a implantable male incontinence device.
GT Urological already has one product: the ActiCuf pouch that externally manages incontinence in men. But the company has received more than $2 million in federal research and business development grants to create implantable devices for men and women that would re-establish urinary control and provide “on demand” control of bladder functions.
Chief Financial Officer Jeff Shapiro said the new money would continue research on the men’s version of the product. A version for women is “down the road,” Shapiro said, though he declined to give a commercilization timetable for either device.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This is the first time the company has raised private equity. In July it selected as its chief medical advisor Dr. Steven Siegel, director of Continence Care at Metro Urology in St. Paul.
